Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 13/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928084 | 1.00 | IKZF2 (0.51) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL29928038 | 0.93 | IKZF2 (0.51) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL25133246 | 0.93 | IKZF2 (0.51) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL29927677 | 0.88 | CRBN (0.55) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL20234882 | 0.88 | CRBN (0.55) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL27028400 | 0.87 | IKZF2 (0.50) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL29132058 | 0.85 | IKZF2 (0.52) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL25134274 | 0.85 | IKZF2 (0.52) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL29927455 | 0.85 | IKZF2 (0.52) | IKZF2CRBNIKZF3DDB1ADRA1D | |
| SCHEMBL25133813 | 0.84 | IKZF2 (0.49) | IKZF2CRBNIKZF3DDB1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | IKZF2 1680/4885CRBN 2/4885IKZF3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.